





































Statin (HMG-CoA reductase inhibitors) are widely used 
therapeutically to reduce morbidity and mortality in 
patients with hyperlipidemic cardiovascular disease 
[1,2]. More recently, it has been recognized that the 
benefit of statin therapy is not only based on lipid 
reduction, but also involves direct vascular effects [2,3]. 
In addition, anti-inflammatory activity and prevention 
of thrombosis are major determinants of the statin’s 
benefit in atherosclerotic vascular disease [4-6]. Recent 
reports have revealed that statin modify apoptosis in 
vascular endothelial cells, resulting in altered vascular 
function [7]. It has been demonstrated that the effect of 
statin on matrix metalloproteinases (MMPs) is 
dependent on the inhibition of mevalonate synthesis, 
resulting in production of the mevalonate isoprenoid 
derivatives, farnesyl pyrophosphate and geranylgeranyl  
 
 



































pyrophosphate [8-10]. These properties indicate a 
potential to modify inflammatory disease states such as 
rheumatoid arthritis (RA).  
 
Leung et al. reported that simvastatin markedly 
inhibited not only developing but also established 
collagen-induced arthritis in a mouse model [11, 12]. 
Another report also suggested that statin, by blocking 
HMG-CoA-reductase, inhibited production of MMPs by 
cultured chondrocytes [13]. Moreover, it has been 
shown that mevastatin increases the mRNA levels of 
bone morphogenetic protein-2, aggrecan and collagen 
type II as well as increasing proteoglycan synthesis in 
rat chondrocytes [14]. These findings suggest a possible 
additional mechanism for statin in counteracting 
osteoarthritis (OA) involving cartilage degeneration. 
However, further studies are needed to clarify the exact 
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that they may have the potential to prevent 
degeneration of articular cartilage. We focused on the 
involvement of chondrocyte aging in articular cartilage 
degeneration [15]. Recently, the idea that chondrocyte 
aging is closely associated with the progression of 
cartilage degeneration has been promulgated [16-19]. 
Several reports of age-related changes in articular 
cartilage are consistent with the phenotypes of 
chondrocyte senescence, such as telomere shortening 
and changes in cell morphology, cellular viability and 
matrix protein production, suggesting that chondrocyte 
aging occurs with donor aging [17-19]. Here, we 
demonstrate that statin can protect against catabolic 
stress-induced disability and cellular aging in human 
articular chondrocytes in vitro and has potential as a 











































Statin inhibits IL-1β-induced aging of articular 
chondrocytes 
 
The phenotype of IL-1β-induced cell senescence was 
characterized by an increase in SA-β-Gal activity. IL-1β 
enhanced cellular SA-β-Gal activity in comparison with 
controls (Figure 1A, B, G, p< 0.01). In contrast, 
treatment with statin (1.0 or 10.0 μM, Figure 1C-F) 
reduced the IL-1β-induced expression of this 
senescence marker in chondrocytes (Figure 1G, p< 0.01 







































































Statin maintains the life span of chondrocytes 
 
The mean life-span of chondrocytes in the absence of 
IL-1β-stress was 18.5 ± 3.4 PD (n = 4), whereas the 
mean life-span of IL-1β-stressed chondrocytes was 12.6 
± 3.6 PD (n = 4, p < 0.05 compared to control). 
Treatment with statin (1.0 or 10.0 μM), however, 
prevented the IL-1β-induced shortening of life-span 
(Table 1).  
 
Statin inhibits the catabolic factor-induced 
production of matrix degrading enzymes 
 
IL-1β enhanced production of MMP-1, -3 and -13 in 
cultured chondrocytes (Figure 2A, B, C). Statin at 10.0 
μM significantly inhibited the IL-1β-induced increase in 
production of MMP-1 and -13 (Figure 2A, C), but not 
MMP-3 (Figure 2B), in chondrocytes. 
 
Proteoglycan production from cultured chondrocytes 
To test whether statin-mediated changes affect the 
potential of chondrocytes to produce matrix protein, we 
determined the amount of proteoglycan produced by the 
statin-treated chondrocytes. Whereas treatment with IL-
1β caused a slight decrease  in proteoglycan production 
by chondrocytes, treatment with statin at 1.0 μM 
showed a tendency to maintain proteoglycan production 
even in the presence of IL-1β (Figure 2D). Treatment 
with statin at 10.0 μM significantly increased the 
production of proteoglycan even in the IL-1β-stressed 
























Treatment with statin protects against the develop-
ment of cartilage degeneration in OA model mice 
 
In the control joints, after 12 and 24 weeks the 
following changes were observed: An extension of the 
area of surface fibrillation, chondrocyte clustering, 
abnormal distribution of chondrocytes, reduced 
proteoglycan staining and decreased cell density with 
cartilage thinning (Figure 3A, B). After 24 weeks of 
treatment, most of the control cartilage showed a 
decrease in thickness, a marked loss of proteoglycan, 
chondrocyte clustering and cell death (Figure 3B). As 
shown in the representative images shown in Figure 4 A 
and B, treatment with statin markedly inhibited the 
degeneration of articular cartilage in the OA mouse 
model. 
 
At 12 weeks, the degree of cartilage degeneration 
tended to be more severe in the control group than in 
the statin treated group. At 24 weeks, mild cartilage 
damage was observed in the statin treated group, 
whereas more severe damage was observed in the 
control group (Figure 4, * p< 0.05, ** p< 0.01 




The studies reported here sought to ascertain whether 
statin can function as a protective agent against 
catabolic stress-induced degeneration of articular 
cartilage in an OA model in vitro and in vivo. Our 
results indicate that statin inhibits the following 
Table 1. Inhibitory effect of statin to chondrocyte life‐span 
 
Group  In vitro life-span (remaining replicative capacity) 
Populating doubling 
Control  18,5 ± 3,4 
IL-β     12,6  ± 3,6  
a 
Simvastatin (1Mμ) 19,4  ± 3,3 
Simvastatin (10 Mμ) 16,8  ± 5,0 
IL-1 (10 ng/ml) +  Simvastatin 1Mμ      20.3 ± 4.2  
b 
IL-1 (10 ng/ml) +  Simvastatin 1Mμ      17.8 ± 3,0  
c 
 
a  p < 0.01, compared to control 
b and 
c p < 0.01 compared to IL-1β-stimulated group 
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enzymes (MMP-1 and -13), down-regulation of 
production of matrix proteins and cellular senescence in 



















































1β. In addition, we found that statin significantly 
reduced articular cartilage degeneration in an OA mouse 
model, an experimental model which spontaneously 





















































of  matrix  degrading  enzymes  and  proteo‐
glycan  in  chondrocytes.  Chondrocytes  were
incubated with catabolic factor, IL‐1β (10 ng/ml)
in the presence or absence of statin (1.0, 10.0





by  chondrocytes  in  control  cultures  (*  p<  0.05













www.impactaging.com                   993                                   AGING,    December 2010, Vol.2 No.12In the present study, we demonstrate that statin has the 
ability to inhibit senescence of articular chondrocytes 
stressed by the catabolic factor, IL-1β. Our results 
indicate that treatment with statin prevents acquisition 
of the phenotype associated with cellular senescence 
which is accelerated by IL-1β treatment. Treatment with 
statin decreased the enhancement of SA-β-Gal activity 
induced by IL-1β. In addition, statin inhibited the IL-











































Recent studies on human articular chondrocytes from 
donors ranging in age from 1 to 87 years showed that 
senescence-associated beta-galactosidase (SA-β-Gal) 
activity increased with age, whereas both mitotic 
activity and mean telomere length declined [17]. 
Previous reports indicated that chondrocyte senescence 
occurs throughout life in vivo [18,19]. This indirect 
evidence supports the hypothesis that age-related 
changes in articular cartilage increase the vulnerability 
of the tissue to degeneration and that the association 
between OA and aging is due, at least in part, to 
chondrocyte senescence. Furthermore, increased SA-β-
Gal activity was observed in damaged OA cartilage, and 
mean telomere length was lower in cells near the lesion 
compared to distal sites in the same joint [19, 20]. These 
findings suggest that chondrocyte senescence, at least in 
part, participates in the pathogenesis of OA. However, 
the exact mechanism of chondrocyte senescence and its 
implications for the pathogenesis of OA still remain 
unclear.  
 
Cellular senescence is classified into 2 types, intrinsic 
telomere-dependent replicative senescence and extrinsic 
telomere-independent senescence. There is a general 
consensus that extrinsic senescence is induced by 
several types of stress, such as oxidative stress or pro-
inflammatory cytokines [21-23]. Numerous catabolic 
stresses involving mechanical loading, cytokines, and 
oxidative stress are involved in the pathophysiology of 
OA. Our previous study revealed that catabolic factors 
may result in extrinsic stress-induced senescence of 
articular chondrocytes [24]. In the current study, our 
data on the inhibitory effects of statin on chondrocyte 
senescence (stress-induced extrinsic senescence) may be 
important in devising new approaches to the prevention 
and treatment of OA, although further studies are 
needed to clarify the mechanism responsible for the 
inhibitory effect of statin on chondrocyte aging. Statin 
is known to have anti-oxidative and anti-inflammatory 
potential [2,3,11,12]. The inhibitory effect of statin on 
IL-1β-induced chondrocyte senescence may be based 
on its anti-inflammatory or anti-oxidative potential. 
Data from other studies suggest that the anti-oxidative 
and anti-inflammatory properties of statin may vary. 
Thus, further studies could be needed to analyze 
whether these effects of statin represent a class effect or 
are specific for particular statin. 
 
In our previous study, we demonstrated that catobolic 
factors acting on articular cartilage, such as 
proinflammatory cytokines and oxidative stress, 
induced senescent cellular phenotypes in chondrocytes: 
Changes in cell morphology, shortening of cellular 
replicative lifespan, telomere shorting and cell cycle 
arrest [15] suggesting that OA–related catabolic factors 
accelerate chondrocyte senescence and the related 
degeneration of articular cartilage. However, it still 
remains unclear why catabolic factors induce 





chondrocytes,  and  a  decreased  cell  density  with  cartilage
thinning. The cartilage in the statin‐treated mice showed less
severe  in  contrast to  the  control  group.  (B)    After  24‐week
treatment, most of the control cartilage showed decrease in
thickness,  marked  loss  of  proteoglycan,  chondrocyte




































activation of mTOR (target of rapamycin) is closely 
involved in cellular senescence [25-37]. Demidenko et 
al. clearly demonstrated that growth stimulation coupled 
with cell cycle arrest leads to senescence, whereas 
quiescence (a condition with inactive TOR) prevents 
senescence [26, 27]. They also demonstrated that an 
inhibitor of mTOR, rapamycin, decelerates cellular 
senescence [25]. Dumont et al. reported that 
proliferation of T cells was stimulated by IL-1 and that 
rapamycin significantly decreased the IL-1-stimulated 
proliferation of T cells, suggesting that IL-1 stimulates 
mTOR pathway [28]. This suggests that IL-1 
accelerates the cellular senescence.  The  activation  of  
mTOR may thus be implicated in chondrocyte 
senescence in OA. Although further studies are needed 
to clarify the exact mechanism of catabolic stress-
induced chondrocyte senescence, the activation of 
mTOR may be implicated in the chondrocyte 
senescence in OA. 
 
In conclusion, our in vitro and in vivo findings suggest 
that statin may have the potential to prevent catabolic 

































and accelerated cellular aging in articular cartilage. 
Statin may thus have a therapeutic effect on articular 
cartilage degeneration. 
 
MATERIALS AND METHODS 
 
Isolation and culture of chondrocytes.  Full-thickness 
human articular cartilage samples were collected from 
the joints of 4 individuals with OA (70, 72, 76, 77 years 
old) who underwent arthroplastic knee surgery. 
Informed consent was obtained in accordance with the 
local ethical commission requirements. The harvested 
cartilage samples were chopped up and digested 
overnight in Dulbecco’s modified Eagle´s medium 
(DMEM), containing 0.5 mg/ml of pronase E and 0.5 
mg/ml of type II collagenase at 37°C. The resulting 
single cell suspension was filtered through a 70-μm 
mesh nylon strainer, and the cells were incubated at 
37°C in a 5% CO2 humidified atmosphere in DMEM 
containing 10% FCS, 2 mM L-glutamine, 100 units/ml 
penicillin and 100 μg/ml streptomycin. To avoid loss of 
the chondrocyte phenotype with successive passages, 
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activity. When cells reached subconfluence, the 
monolayers were subjected to enzymatic dissociation 
with trypsin and seeded onto new dishes. In the 
presence or absence of titrated concentrations of statin 
(1.0 or 10.0 μM, Kaken Pharm. Co. Ltd., Tokyo, Japan), 
the chondrocytes were stimulated with 10 ng/ml 
interleukin (IL)-1β for 5 days.  
 
To investigate senescence, the SA-β-gal activity in 
cultured chondrocytes was detected as previously 
described (29),
  using the Senescence Detection Kit 
(BioVision, Mountain View, CA) according to the 
manufacturer’s recommendations. Cells were 
photographed under reflected light using a VH-8000 
digital high fidelity microscope (Keyence, Osaka, 
Japan). The number of SA-β-gal positive cells/field was 
counted in 10 fields/slide and the mean number of 
positive cells/field (x 200) was calculated.  
 
Cellular lifespan of chondrocytes. The cells were 

































statin (1.0 or 10.0 μM). At each subculture, the total 
number of cells was determined by counting in a 
haemocytometer, and cells were transferred to new 
dishes at a ratio of 1:3. The non-adherent cells were 
counted 6 h post-seeding, and their number subtracted 
from the number of seeded cells. The increase in 
cumulative population doublings at each subculture was 
calculated based on the number of cells attached and the 
cell yield at the time of the next subcultivation. The end 
of the replicative lifespan was defined by failure of the 
population to double after 4 weeks in mass culture. The 
in vitro life-span (remaining replicative capacity) was 
expressed as population doublings (PD) up to cellular 
senescence. Population doublings were calculated 
using the following equation: PD = Log10 (N/N0) 
×3.33, where N is the number of cells at the end and 
N0 is the number of cells at the beginning of the 
experiment [29,30]. To maintain the phenotypic 
characteristics of the chondrocytes during serial 
passage for determination of life-span, we used 
CGM
TM BulletKit
®  (chondrocyte growth medium) 




































Safranin O-fast green staining 
  0 = uniform staining throughout articular cartilage 
  1 = loss of staining in the superficial zone for less than one-half of the length of the plateau 
  2 = loss of staining in the superficial zone for one-half or more of the length of the plateau 
  3 = loss of staining in the superficial and middle zones for less than one-half of the length of the 
plateau 
  4 = loss of staining in the superficial and middle zones for one-half or more of the length of the 
plateau 
  5 = loss of staining in all 3 zones for less than one-half of the length of the plateau 
  6 = loss of staining in all 3 zones for one-half or more of the length of the plateau 
 
Chondrocyte loss 
 0 = no decrease in cells 
 1 = minimal decrease in cells 
 2 = moderate decrease in cells 
 3 = marked decrease in cells 
 4 = very extensive decrease in cells 
 
Structure 
 0 = normal 
 1 = surface irregularities 
 2 = 1-3 superficial clefts 
 3 = >3 superficial clefts 
 4 = 1-3 clefts extending into the middle zone 
 5 = >3 clefts extending into the middle zone 
 6 = 1-3clefts extending into the deep zone 
 7 = >3 clefts extending into the deep zone 
 8 = clefts extending to calcified cartilage  
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chondrocytes. To measure the catabolic activity of 
chondrocytes, levels of MMP-1, -3 and -13 produced by 
chondrocytes were measured using an ELISA kit 
(MMP-1: Amersham Biosciences, Buckinghamshire, 
UK; MMP-3: R&D Systems Inc., Minneapolis, MN; 
MMP-13: Amersham Biosciences).  
 
To examine the effect of statin on anabolic activity in 
chondrocytes, the levels of proteoglycan produced by 
chondrocytes in culture were measured using an 
enzyme-linked immunosorbent assay (ELISA) kit in 
accordance with the manufacturer's protocol (BioSource 
Europes S.A., Nivelles, Belgium). 
 
Animals and administration protocols. The study was 
performed on STR/OrtCrlj mice, an experimental model 
strain which spontaneously develops an osteoarthritic 
process. STR/OrtCrlj mice (male, 12 weeks of age) 
were purchased from Charles
 River Japan (Yokohama, 
Japan). The mice were maintained in a
 temperature (23–
25 °C)-, humidity (40–60%)-,
  and light-controlled 
environment with free access to an MF diet
 (Japan SLC 
Co. Ltd., Shizuoka, Japan) and water. They were 
acclimatized
 for at least 1 week before the start of the 
study. Twenty-four animals were divided into 2 groups 
(statin-fed or control). The statin-fed
 group received 40 
mg/kg/day of statin by daily gavage for 24 weeks. The
 
control group were given saline by daily gavage for 24 
weeks. The care and use of
 the experimental animals in 
this study followed "The Ethical
 Guidelines of Animal 
Care, Handling and Termination" prepared
  by the 
National Institute of Health Sciences of Japan. The mice 
were euthanized after 12 or 24 weeks of treatment and 
both knee joints were harvested. Bone and cartilage 
tissue blocks were prepared for histological analysis.  
 
Articular cartilage lesion score. Each cartilage sample 
was evaluated histologically for the degree of 
degeneration according to a modified Mankin grading 
system (31). Articular cartilage samples together with 
subchondral bone were fixed for 2 days in 4% 
paraformaldehyde solution and then decalcified in 4% 
paraformaldehyde containing 0.85% sodium chloride 
and 10% acetic acid. Tissues were dehydrated through a 
series of ethanol solutions and infiltrated with xylene 
before being embedded in paraffin and cut into 6 μm 
sections. Sections were deparaffinized through 
sequential immersion in xylene and a graded series of 
ethanol solutions in accordance with conventional 
procedures. The sections were stained with Safranin O-
fast green or hematoxylin-eosin. The mean damage 
score from the 6 - 8 samples from each animal was used 
to determine the mean ± standard deviation for each 
group. Three independent observers assessed cartilage 
damage in a blinded manner. 
 
Statistical analysis. Results are expressed as means ± 
standard deviations. Data were analyzed using a 
nonparametric statistical method. A P value < 0.05 was 
considered statistically significant.  
 
Student’s t -test was used to assess the differences 
between statin-treated and control groups with respect 
to histologic parameters (Safranin O-fast green staining, 
structure, chondrocyte loss; Table 2) of the tibial 
plateau in the isolated knee joints. When a statistically 
significant difference between the 2 groups was 
detected, analysis of variance (ANOVA) was used to 
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